Online citations, reference lists, and bibliographies.
← Back to Search

Conventional And Nanotechnology Based Approaches To Combat Chronic Obstructive Pulmonary Disease: Implications For Chronic Airway Diseases

Mehak Passi, Sadia Shahid, Sankarakuttalam Chockalingam, I. Sundar, Gopinath Packirisamy
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Chronic obstructive pulmonary disease (COPD) is the most prevalent obstructive lung disease worldwide characterized by decline in lung function. It is associated with airway obstruction, oxidative stress, chronic inflammation, mucus hypersecretion, and enhanced autophagy and cellular senescence. Cigarette smoke being the major risk factor, other secondary risk factors such as the exposure to air pollutants, occupational exposure to gases and fumes in developing countries, also contribute to the pathogenesis of COPD. Conventional therapeutic strategies of COPD are based on anti-oxidant and anti-inflammatory drugs. However, traditional anti-oxidant pharmacological therapies are commonly used to alleviate the impact of COPD as they have many associated repercussions such as low diffusion rate and inappropriate drug pharmacokinetics. Recent advances in nanotechnology and stem cell research have shed new light on the current treatment of chronic airway disease. This review is focused on some of the anti-oxidant therapies currently used in the treatment and management of COPD with more emphasis on the recent advances in nanotechnology-based therapeutics including stem cell and gene therapy approaches for the treatment of chronic airway disease such as COPD and asthma.
This paper references
New developments in liposomal drug
BS Pattni (2015)
10.1016/j.addr.2008.09.011
Extracellular barriers in respiratory gene therapy☆
N. Sanders (2009)
10.2147/COPD.S87091
Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD
M. Moretti (2015)
10.1016/j.addr.2011.05.004
Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery.
Jin-Wook Yoo (2011)
10.1517/14712598.5.3.333
Gene therapy for chronic obstructive pulmonary disease: twilight or triumph?
R. Al-Jamal (2005)
10.1183/13993003.00592-2015
Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis
J. Elborn (2015)
10.1016/j.nano.2012.04.005
Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study.
Biswadip Sinha (2013)
10.1183/13993003.00711-2017
Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study
R. D. Dal Negro (2017)
10.1021/nl801488u
Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.
K. C. Weng (2008)
10.1016/j.colsurfb.2009.02.001
Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer.
Keishiro Tomoda (2009)
10.1038/emm.2007.82
A novel thiol compound, N-acetylcysteine amide, attenuates allergic airway disease by regulating activation of NF-κB and hypoxia-inducible factor-1α
K. S. Lee (2007)
10.1007/s12551-017-0319-x
New perspectives in nanotherapeutics for chronic respiratory diseases
A. L. da Silva (2017)
10.1016/j.freeradbiomed.2010.09.022
Endogenous enzymes (NOX and ECSOD) regulate smoke-induced oxidative stress.
Angela K. Tollefson (2010)
10.1371/journal.pone.0216711
Curcumin attenuates oxidative stress in RAW264.7 cells by increasing the activity of antioxidant enzymes and activating the Nrf2-Keap1 pathway
Xinyu Lin (2019)
10.1080/10717544.2017.1402217
Surfactant protein-A nanobody-conjugated liposomes loaded with methylprednisolone increase lung-targeting specificity and therapeutic effect for acute lung injury
N. Li (2017)
10.1016/j.ejpb.2004.03.008
PLGA–PEI nanoparticles for gene delivery to pulmonary epithelium
M. Bivas-Benita (2004)
10.2147/IJN.S25363
Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations
M. Sahib (2011)
Applicability of induced sputum for molecular dosimetry of exposure to inhalatory carcinogens: 32P-postlabeling of lipophilic DNA adducts in smokers and nonsmokers.
A. Besaratinia (2000)
10.1016/j.addr.2010.08.004
Imaging and drug delivery using theranostic nanoparticles.
S. M. Janib (2010)
10.1016/S0002-9440(10)65006-7
Openings between defective endothelial cells explain tumor vessel leakiness.
H. Hashizume (2000)
10.1007/s00408-007-9065-3
Erdosteine: antitussive and anti-inflammatory effects.
R. D. Dal Negro (2008)
Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography.
R. Kubota (1992)
10.1126/scisignal.3112re3
Stress-Activated Cap'n'collar Transcription Factors in Aging and Human Disease
G. Sykiotis (2010)
10.1371/journal.pone.0040775
The Interplay of Lung Surfactant Proteins and Lipids Assimilates the Macrophage Clearance of Nanoparticles
Christian A. Ruge (2012)
10.1186/1471-2466-12-38
Intratracheally administered titanium dioxide or carbon black nanoparticles do not aggravate elastase-induced pulmonary emphysema in rats
A. Roulet (2012)
10.1007/S11051-008-9446-4
Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies
Jingkun Jiang (2009)
10.1038/nnano.2012.207
Biomolecular coronas provide the biological identity of nanosized materials.
M. Monopoli (2012)
10.1186/1743-8977-11-19
Biokinetics of nanoparticles and susceptibility to particulate exposure in a murine model of cystic fibrosis
M. Geiser (2013)
10.1016/j.addr.2008.11.002
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.
S. Lai (2009)
10.1073/pnas.0804333106
Targeting Nrf2 with the triterpenoid CDDO- imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice
T. Sussan (2009)
10.1007/s00408-007-9065-3
Erdosteine: Antitussive and Anti-inflammatory Effects
R. Negro (2007)
10.1186/s12931-016-0500-y
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation
M. Cazzola (2017)
10.1007/BF00609183
Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration
J. M. Burgunder (2004)
10.1016/J.BBRC.2005.03.237
Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells.
Chu-Yue Chen (2005)
10.1152/ajplung.90443.2008
Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice.
M. Suzuki (2009)
10.1016/S0954-6111(97)90052-4
Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro.
A. Gillissen (1997)
10.1016/j.freeradbiomed.2019.08.012
Sulforaphane protects from myocardial ischemia-reperfusion damage through the balanced activation of Nrf2/AhR.
A. Silva-Palacios (2019)
10.1080/03639045.2017.1318895
Development of drug-loaded chitosan hollow nanoparticles for delivery of paclitaxel to human lung cancer A549 cells
J. Jiang (2017)
10.1378/CHEST.125.4.1500
Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats.
M. L. Rubio (2004)
Surfactant protein-A nanobodyconjugated liposomes loaded with methylprednisolone increase lung-targeting specificity and therapeutic effect for acute lung injury
N Li (2017)
Interaction of soot derived multi-carbon nanoparticles with lung surfactants and their possible internalization inside alveolar cavity.
P. Kumar (2010)
10.1152/JAPPLPHYSIOL.00007.2002
Selected contribution: Lung hypoxia: antioxidant and antiapoptotic effects of liposomal alpha-tocopherol.
T. Minko (2002)
10.3109/1061186X.2011.622404
Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA
O. Taratula (2011)
10.1016/J.PUPT.2004.09.030
Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD.
F. De Benedetto (2005)
10.2147/IJN.S59394
MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles
A. Al Faraj (2014)
10.2147/IJN.S69845
Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood–brain barrier
X. Wang (2014)
10.1517/17425247.2012.735658
Liposomal delivery of proteins and peptides
Janani Swaminathan (2012)
10.1016/j.bbagen.2011.07.016
The transferrin receptor and the targeted delivery of therapeutic agents against cancer.
T. R. Daniels (2012)
10.1038/nbt.3330
Principles of nanoparticle design for overcoming biological barriers to drug delivery
E. Blanco (2015)
10.1007/s00011-011-0409-3
The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures
M. Monument (2011)
10.1093/NAR/GNH153
Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer.
B. Pitard (2004)
10.1186/1743-8977-10-19
Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease
M. Geiser (2013)
10.1517/17425247.5.6.629
Biodegradable polymeric nanocarriers for pulmonary drug delivery.
E. Rytting (2008)
10.1039/C5TB00572H
Antioxidant nanozyme: a facile synthesis and evaluation of the reactive oxygen species scavenging potential of nanoceria encapsulated albumin nanoparticles.
Bharat Bhushan (2015)
10.1021/nl5048972
Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature.
Omar F Khan (2015)
10.1152/JAPPLPHYSIOL.01429.2005
FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin.
D. Chen (2006)
10.1155/2013/509130
Oxidative stress in chronic obstructive pulmonary disease: a lung and systemic process.
S. V. van Eeden (2013)
10.1183/09031936.00018508
Effect of fudosteine on mucin production
C. Rhee (2008)
10.1034/J.1399-3003.2000.16B12.X
The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
C. Stey (2000)
10.2147/COPD.2006.1.2.99
The role for N-acetylcysteine in the management of COPD
P. Dekhuijzen (2006)
10.1021/acs.biomac.7b00572
Anti-Inflammatory Effect of Anti-TNF-α SiRNA Cationic Phosphorus Dendrimer Nanocomplexes Administered Intranasally in a Murine Acute Lung Injury Model.
A. Bohr (2017)
Involvement of Nrf2, p38, B-raf and NF- B, but not PI3K, in induction of hemeoxygenase (HO-1) by dietary polyphenols
CK Andreadi (2005)
10.1111/j.1440-1843.2009.01594.x
Carbocisteine inhibits oxidant‐induced apoptosis in cultured human airway epithelial cells
M. Yoshida (2009)
Bone marrow mesenchymal stem cell transplantation for treatment of emphysemic rats.
Y. Zhao (2014)
10.1016/S0891-5849(01)00820-6
Nacystelyn inhibits oxidant-mediated interleukin-8 expression and NF-kappaB nuclear binding in alveolar epithelial cells.
F. Antonicelli (2002)
10.1248/YAKUSHI.127.1549
[Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid].
H. Hatakeyama (2007)
10.1165/RCMB.2004-0330OC
Bone marrow-derived mesenchymal stem cells in repair of the injured lung.
M. Rojas (2005)
10.1111/j.1348-0421.1999.tb02381.x
The Effects of S‐Carboxymethylcysteine and N‐Acetylcysteine on the Adherence of Moraxella catarrhalis to Human Pharyngeal Epithelial Cells
C. Zheng (1999)
10.1074/jbc.M110.121913
The Ubiquitin-conjugating Enzyme UbcM2 Can Regulate the Stability and Activity of the Antioxidant Transcription Factor Nrf2*
K. Plafker (2010)
10.1021/acs.molpharmaceut.7b00532
In Vivo Pulmonary Delivery and Magnetic-Targeting of Dry Powder Nano-in-Microparticles
Dominique N. Price (2017)
10.1016/j.ijpharm.2011.12.045
A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles.
Y. Wang (2012)
10.1378/CHEST.107.2_SUPPLEMENT.77S
Gene therapy for cystic fibrosis.
L. G. Johnson (1995)
10.1517/17425247.2011.597381
Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential
N. Vij (2011)
10.1007/s00408-011-9360-x
Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
L. Willis (2011)
10.1038/nmat2442
Understanding biophysicochemical interactions at the nano-bio interface.
A. Nel (2009)
10.1021/mp800051m
Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles
F. Alexis (2008)
10.5414/CPP49041
Erdosteine affects eicosanoid production in COPD.
R. D. Dal Negro (2011)
10.1016/J.IJANTIMICAG.2005.07.012
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
Zahoor Ahmad (2005)
10.1208/s12249-014-0182-z
High-Performing Dry Powder Inhalers of Paclitaxel DPPC/DPPG Lung Surfactant-Mimic Multifunctional Particles in Lung Cancer: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies
S. Meenach (2014)
10.1016/J.PUPT.2004.11.002
Inhibition of endotoxin- and antigen-induced airway inflammation by fudosteine, a mucoactive agent.
H. Komatsu (2005)
10.1124/JPET.104.068205
The Protective Effect of Superoxide Dismutase Mimetic M40401 on Balloon Injury-Related Neointima Formation: Role of the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1
C. Muscoli (2004)
10.1021/ar200105p
Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.
Wafa’T. Al-Jamal (2011)
10.2147/COPD.2006.1.1.15
Antioxidant therapies in COPD
I. Rahman (2006)
10.1016/S0167-7799(97)01036-6
Biomedical applications of nanotechnology--implications for drug targeting and gene therapy.
S. Davis (1997)
10.1038/sj.gt.3301947
Gene Therapy Progress and Prospects: Alpha-1 antitrypsin
A. Stecenko (2003)
10.1182/BLOOD.V99.3.912
Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells.
R. Wiewrodt (2002)
10.1042/BJ20020154
Oxidation of nitric oxide by oxomanganese-salen complexes: a new mechanism for cellular protection by superoxide dismutase/catalase mimetics.
M. Sharpe (2002)
10.1164/RCCM.200212-1479SO
Superoxide dismutases in the lung and human lung diseases.
V. Kinnula (2003)
10.1016/j.intimp.2014.12.018
Carbocisteine attenuates hydrogen peroxide-induced inflammatory injury in A549 cells via NF-κB and ERK1/2 MAPK pathways.
W. Wang (2015)
10.1038/sj.gt.3302843
Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid
H. Hatakeyama (2007)
10.1016/j.coph.2012.01.015
Antioxidant pharmacological therapies for COPD.
I. Rahman (2012)
10.1371/journal.pone.0008391
Dihydro-CDDO-Trifluoroethyl Amide (dh404), a Novel Nrf2 Activator, Suppresses Oxidative Stress in Cardiomyocytes
T. Ichikawa (2009)
10.1038/mt.2011.160
N-acetylcysteine Enhances Cystic Fibrosis Sputum Penetration and Airway Gene Transfer by Highly Compacted DNA Nanoparticles.
J. Suk (2011)
10.1016/j.ejpb.2012.11.023
Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.
V. Ivanova (2013)
10.3390/pharmaceutics8010006
Development of Liposomal Ciprofloxacin to Treat Lung Infections
D. Cipolla (2016)
10.1073/PNAS.96.19.10824
BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy.
P. E. Chabrier (1999)
10.1073/PNAS.0600997103
Role of target geometry in phagocytosis.
J. Champion (2006)
10.1021/bc8000722
Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery.
M. L. Patil (2008)
10.1039/C5ME00004A
Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway.
P. Muralidharan (2016)
10.1002/jcp.24282
Activation of canonical wnt pathway promotes differentiation of mouse bone marrow‐derived MSCs into type II alveolar epithelial cells, confers resistance to oxidative stress, and promotes their migration to injured lung tissue in vitro
Ai-ran Liu (2013)
10.2174/1568026614666140329225817
Nanocarriers for respiratory diseases treatment: recent advances and current challenges.
A. Trapani (2014)
10.1016/J.JCONREL.2012.08.014
Crucial factors and emerging concepts in ultrasound-triggered drug delivery.
B. Geers (2012)
10.1165/RCMB.2002-0228OC
Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade.
R. Tuder (2003)
Anti-inflammatory effect of anti-TNF-α SiRNA cationic phosphorus dendrimer nanocomplexes administered intranasally in a murine acute lung injury
A Bohr (2017)
10.1016/j.jconrel.2014.03.012
Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.
L. M. Kaminskas (2014)
10.1073/pnas.0607260103
DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2
C. Clements (2006)
10.1016/J.JCONREL.2004.02.003
Folate receptor targeted biodegradable polymeric doxorubicin micelles.
H. Yoo (2004)
Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease
Andrew J Thorley (2007)
10.4049/jimmunol.169.2.974
Differential Effects of Ebselen on Neutrophil Recruitment, Chemokine, and Inflammatory Mediator Expression in a Rat Model of Lipopolysaccharide-Induced Pulmonary Inflammation
E. Haddad (2002)
10.1007/s11095-008-9626-z
Shape Induced Inhibition of Phagocytosis of Polymer Particles
J. Champion (2008)
10.4155/tde.12.105
Application of polysaccharides for surface modification of nanomedicines.
Kyung-Oh Doh (2012)
10.1016/S0954-6111(06)80220-9
N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study.
M. Dueholm (1992)
Longlasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis
PC Braga (1958)
10.1016/S0891-5849(01)00825-5
Ebselen suppresses late airway responses and airway inflammation in guinea pigs.
Minjie Zhang (2002)
10.1073/pnas.1007625107
Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM
H. Yao (2010)
10.1039/c3np70065h
Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases.
H. Kumar (2014)
10.1016/S0891-5849(02)01003-1
Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant.
K. R. Smith (2002)
10.1016/j.taap.2009.10.022
Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease.
Hongwei Yao (2011)
Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways.
Adler Kb (1986)
10.1016/j.pupt.2009.02.003
Ginkgo biloba extract confers protection from cigarette smoke extract-induced apoptosis in human lung endothelial cells: Role of heme oxygenase-1.
Chiu-ling Hsu (2009)
10.1152/AJPLUNG.00361.2007
Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells.
A. Kode (2008)
10.2147/COPD.S3735
The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease
C. Hooper (2008)
The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis : a meta-analysis of individual patient data
M. Cazzolaa (2018)
10.1038/jcbfm.2010.53
The Flavanol (−)-Epicatechin Prevents Stroke Damage through the Nrf2/HO1 Pathway
Z. Shah (2010)
10.14797/MDCJ-8-1-36
Liposomes in diagnosis and treatment of cardiovascular disorders.
T. Levchenko (2012)
10.1016/J.JHEP.2007.02.008
Quercetin protects human hepatocytes from ethanol-derived oxidative stress by inducing heme oxygenase-1 via the MAPK/Nrf2 pathways.
P. Yao (2007)
10.1016/j.jconrel.2015.07.024
Nanotechnology approaches for inhalation treatment of lung diseases.
A. Kuzmov (2015)
10.1378/CHEST.121.3_SUPPL.91S
Mode of action of RNA/DNA oligonucleotides: progress in the development of gene repair as a therapy for alpha(1)-antitrypsin deficiency.
R. Metz (2002)
10.1016/j.freeradbiomed.2009.07.035
Nrf2:INrf2 (Keap1) signaling in oxidative stress.
James W Kaspar (2009)
10.7497/j.issn.2095-3941.2014.01.004
Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention
O. Garbuzenko (2014)
Role of protein kinase C δ in curcumin-induced antioxidant response element-mediated gene expression in human monocytes
SA Rushworth (2006)
10.1183/09031936.00212813
Medical nanoparticles for next generation drug delivery to the lungs
S. H. van Rijt (2014)
10.1158/0008-5472.CAN-05-3513
Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells.
Young-Sam Keum (2006)
MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibodyconjugated magnetic nanoparticles
A Al Faraj (2014)
10.1002/wnan.1157
Recent advances in stealth coating of nanoparticle drug delivery systems.
Z. Amoozgar (2012)
10.1016/j.toxlet.2013.09.013
Carbocysteine regulates innate immune responses and senescence processes in cigarette smoke stimulated bronchial epithelial cells.
E. Pace (2013)
10.1021/nn800072t
Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery.
M. Liong (2008)
10.1517/14656560902758343
Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases.
A. Macciò (2009)
10.1038/nnano.2007.70
Shape effects of filaments versus spherical particles in flow and drug delivery.
Y. Geng (2007)
10.1021/acsnano.6b06061
Aerosol Delivery of Functionalized Gold Nanoparticles Target and Activate Dendritic Cells in a 3D Lung Cellular Model.
K. Fytianos (2017)
10.4155/tde.13.6
Receptor-based targeting of therapeutics.
N. K. Mehra (2013)
10.1016/j.resp.2009.04.016
l-Carbocisteine reduces neutrophil elastase-induced mucin production
M. Yasuo (2009)
10.1016/S0891-5849(03)00439-8
Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes.
L. József (2003)
10.1021/acs.chemrev.5b00046
New Developments in Liposomal Drug Delivery.
Bhushan S. Pattni (2015)
10.1124/MOL.105.018374
Involvement of Nrf2, p38, B-Raf, and Nuclear Factor-κB, but Not Phosphatidylinositol 3-Kinase, in Induction of Hemeoxygenase-1 by Dietary Polyphenols
C. Andreadi (2006)
Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways.
K. B. Adler (1986)
10.1021/nn901796n
Labile catalytic packaging of DNA/siRNA: control of gold nanoparticles "out" of DNA/siRNA complexes.
A. M. Chen (2010)
10.1517/17425247.3.5.563
pH-responsive shielding of non-viral gene vectors
M. Meyer (2006)
The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
M. Moretti (2004)
10.1016/B978-0-12-815720-6.00007-1
Dendrimer-Based Nanocarriers in Lung Cancer Therapy
Bapi Gorain (2019)
10.2217/nnm.13.8
Therapeutic nanoparticles in clinics and under clinical evaluation.
Catherine A. Schütz (2013)
10.1038/sj.clpt.6100400
Nanoparticles in Medicine: Therapeutic Applications and Developments
L. Zhang (2008)
10.1016/S0891-5849(02)00919-X
Inhibition of airway inflammation and hyperreactivity by an antioxidant mimetic.
L. Chang (2002)
10.1165/rcmb.2009-0459OC
Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine.
S. Hodge (2011)
10.1016/j.bcp.2008.02.029
Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme.
Ha-Yong Yoon (2008)
acetylcysteine for antioxidant therapy: pharmacology and clinical utility
S Dodd (1962)
10.1152/AJPLUNG.00329.2003
Regulation of LPS-mediated inflammation in vivo and in vitro by the thiol antioxidant Nacystelyn.
F. Antonicelli (2004)
10.1517/17425250902814790
Erdosteine: its relevance in COPD treatment.
Maurizio Moretti (2009)
10.1089/ars.2010.3222
Discovery of the negative regulator of Nrf2, Keap1: a historical overview.
K. Itoh (2010)
10.1159/000195871
Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis.
P. Braga (1990)
10.1034/J.1399-3003.1999.13D22.X
N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis.
A. Ekberg-Jansson (1999)
10.1517/14728220802517901
N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility.
S. Dodd (2008)
10.1183/09031936.04.00069004
Does systemic inflammation trigger local exercise-induced oxidative stress in COPD?
C. Koechlin (2004)
10.1016/S0882-4010(03)00048-2
S-carboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells.
Gulcin Cakan (2003)
10.1016/j.jconrel.2010.11.001
Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model.
Y. J. Oh (2011)
Clinical evaluation of acetylcysteine in the treatment of patients with chronic obstructive bronchitis: a balanced double-blind trial with placebo control.
M. Aylward (1980)
10.3390/jcm5090082
Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery
J. Y. Yhee (2016)
10.1378/chest.08-2105
Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine.
G. Osoata (2009)
10.1146/ANNUREV.PHARMTOX.46.120604.141046
Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway.
T. Kensler (2007)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar